INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/GiftVerified data

Onyia Jude reported NBIX

Chief Scientific Officer · NEUROCRINE BIOSCIENCES INC · Common Stock

Side
G
Value
—
Shares
2,441
Price
—
Executed
Jun 5, 2026
Disclosed
Jun 9, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jun 5 executedJun 9, 2026 disclosed

NBIX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
12/ 100 · ROUTINE
Methodology →
  • Transaction type+3 / 20

    Gift

  • Relative size+5 / 25

    No reported dollar value · 11.6% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · NBIX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    OJ
    Onyia JudeChief Scientific Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Grant or award
    		A—
    3,587 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    18
    BW
    Boyer David W.Chief Corp. Affairs Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Open-market sale · 10b5-1 plan
    		SELL$130K
    826 sh
    		Sep 14, 2026Sep 15, 2026
    traded Sep 14, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BW
    Boyer David W.Chief Corp. Affairs Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Tax withholding · 10b5-1 plan
    		F$302K
    1,936 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    13
    DI
    Delaet IngridChief Regulatory Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Grant or award
    		A—
    4,483 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    15
    DI
    Delaet IngridChief Regulatory Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Tax withholding
    		F$378K
    2,419 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    3
    BW
    Boyer David W.Chief Corp. Affairs Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Grant or award · 10b5-1 plan
    		A—
    3,587 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    9
    AM
    Abernethy MattChief Financial Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Tax withholding · 10b5-1 plan
    		F$423K
    2,709 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    3
    AM
    Abernethy MattChief Financial Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Grant or award · 10b5-1 plan
    		A—
    5,020 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    13
    CJ
    Cooke JulieChief Human Resources Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Grant or award
    		A—
    3,587 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    19
    CJ
    Cooke JulieChief Human Resources Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Tax withholding
    		F$302K
    1,936 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    27
    KC
    Keswani Sanjay ChandruChief Medical Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Tax withholding
    		F$330K
    2,112 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    21
    KC
    Keswani Sanjay ChandruChief Medical Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Grant or award
    		A—
    3,914 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    15
    OJ
    Onyia JudeChief Scientific Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Tax withholding
    		F$302K
    1,936 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    25
    AM
    Abernethy MattChief Financial Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Open-market sale · 10b5-1 plan
    		SELL$363K
    2,311 sh
    		Sep 14, 2026Sep 15, 2026
    traded Sep 14, 2026
    		+1dSEC FORM 4

    Evidence

    6
    BE
    Benevich EricChief Commercial Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M$138K
    3,194 sh
    		Sep 9, 2026Sep 10, 2026
    traded Sep 9, 2026
    		+1dSEC FORM 4

    Evidence

    0
    BE
    Benevich EricChief Commercial Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    3,194 sh
    		Sep 9, 2026Sep 10, 2026
    traded Sep 9, 2026
    		+1dSEC FORM 4

    Evidence

    21
    BE
    Benevich EricChief Commercial Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Open-market sale · 10b5-1 plan
    		SELL$333K
    2,154 sh
    		Sep 9, 2026Sep 10, 2026
    traded Sep 9, 2026
    		+1dSEC FORM 4

    Evidence

    15
    KC
    Keswani Sanjay ChandruChief Medical Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Tax withholding
    		F$268K
    1,733 sh
    		Jun 2, 2026Jun 4, 2026
    traded Jun 2, 2026
    		+2dSEC FORM 4

    Evidence

    21
    KC
    Keswani Sanjay ChandruChief Medical Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Option exercise
    		M—
    3,212 sh
    		Jun 2, 2026Jun 4, 2026
    traded Jun 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    KC
    Keswani Sanjay ChandruChief Medical Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Option exercise
    		M—
    3,212 sh
    		Jun 2, 2026Jun 4, 2026
    traded Jun 2, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001894425-26-000014
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 5, 2026
    Published
    Jun 9, 2026
    Ingested by INSIDER
    Nov 5, 03:54 UTC
    Last re-read
    Nov 5, 03:54 UTC

    Extracted facts

    Filer
    Onyia Jude
    Role
    Chief Scientific Officer
    Transaction
    GiftAs filed: “G”
    Asset
    NEUROCRINE BIOSCIENCES INC
    Ticker
    NBIX
    Shares
    2,441
    Price per share
    $0
    Execution date (reported)
    Jun 5, 2026
    Owned after transaction
    23.4K shares
    Days from execution to publication
    4

    What this establishes

    Onyia Jude filed this Form 4 reporting a gift of NBIX on Jun 5, 2026. It became public on Jun 9, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Scientific Officer
    Onyia Judecik:0001894425
    Issuer
    NEUROCRINE BIOSCIENCES INCcik:0000914475

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.